Research To Practice | Oncology Videos

Latest Episodes:

Colorectal Cancer | Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer Oct 06, 2023

Show notes

Featuring perspectives from Dr Kristen K Ciombor and Dr J Randolph Hecht, including the following topics:

Introduction (0:00)
Case: A woman in her early 80s with KRAS-mutated, HER2-positive metastatic colorectal adenocarcinoma — Zanetta S Lamar, MD (14:29)
Case: A man in his late 70s with metastatic KRAS G12C-mutated rectal adenocarcinoma treated with third-line sotorasib/panitumumab — Georges Azzi, MD (26:03)
Cases: A man in his late 50s with KRAS-mutated metastatic colon cancer and very slow disease progression on second-line FOLFIRI/bevacizumab, and a man in his mid 40s with KRAS wild-type metastatic colon cancer and disease progression on third-line treatment — Priya Rudolph, MD, PhD, and Ina J Patel, DO (30:41)
Case: A man in his early 80s with right-sided microsatellite-stable (MSS), KRAS G12D-mutated metastatic colorectal cancer (mCRC), tumor mutational burden 10 mut/Mb, currently receiving third-line TAS-102 — Warren S Brenner, MD (37:11)
Case: A man in his late 70s with microsatellite instability-high, BRAF V600E-mutated recurrent cecal adenocarcinoma — Nikesh Jasani, MD (50:09)
Cases: A woman in her late 50s with MSS BRAF V600E-mutated mCRC with brain and bone metastases who experiences a good response to dose-reduced FOLFOX after disease progression on first-line encorafenib/cetuximab, and a woman in her mid 60s with RAS wild-type, BRAF V600E-mutated, MSS mCRC, now receiving encorafenib/cetuximab after disease progression on FOLFOX/bevacizumab — Farshid Dayyani, MD, PhD, and Dr Azzi (59:05)

CME information and select publications

Colorectal Cancer | J Randolph Hecht, MD Oct 06, 2023

Show notes

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 2: Targeted Treatment for R/R mCRC — J Randolph Hecht, MD

CME information and select publications

Colorectal Cancer | Kristen K Ciombor, MD, MSCI Oct 06, 2023

Show notes

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 1: Nontargeted Treatment Approaches for Relapsed/Refractory (R/R) Metastatic Colorectal Cancer (mCRC) — Kristen K Ciombor, MD, MSCI

CME information and select publications

Blastic Plasmacytoid Dendritic Cell Neoplasm | Oncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell Neoplasm Oct 05, 2023

Show notes

Featuring an interview with Prof Naveen Pemmaraju, including the following topics:

Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00)
Defining and diagnosing BPDCN (5:17)
Presentation, prevention and management of capillary leak syndrome (7:56)
Targeting CD123 in BPDCN (12:53)
Case: A man in his early 70s with TET-mutated BPDCN who had a complete response to tagraxofusp (14:21)
Selection of CD123-targeted therapy for patients with BPDCN (20:05)
Case: A man in his mid 60s who had a complete response to pivekimab sunirine (27:04)
Future directions in the treatment of BPDCN (28:55)

CME information and select publications

Blastic Plasmacytoid Dendritic Cell Neoplasm | Oncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell Neoplasm (Companion Faculty Lecture) Oct 05, 2023

Show notes

Featuring a slide presentation and related discussion from Prof Naveen Pemmaraju, including the following topics:

Overview of blastic plasmacytoid dendritic cell neoplasms (0:00)
Tagraxofusp: Development of the first FDA-approved targeted therapy for BPDCN (9:07)
Integration of pivekimab sunirine into the management of BPDCN (20:31)
Emerging novel therapies for patients with BPDCN and current role of chemotherapy-based regimens (26:02)
Future directions in the management of BPDCN (33:26)

CME information and select publications

Myelofibrosis | Consensus or Controversy? Documenting and Discussing Clinical Investigators' Practice Patterns in Myelofibrosis Oct 04, 2023

Show notes

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, moderated by Dr Mascarenhas, including the following topics:

Introduction (0:00)
Clinical Decision-Making for Patients with Myelofibrosis (MF) — Dr Bose (2:27)
Management of MF in Special Patient Populations — Dr Mascarenhas (19:26)
Future Directions in the Management of MF — Dr Kuykendall (48:09)

CME information and select publications

Breast Cancer | Hope S Rugo, MD Sep 29, 2023

Show notes

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 2: Current and Future Role of Nonbiomarker-Based Strategies for Patients with Metastatic BRCA-Negative TNBC — Hope S Rugo, MD

CME information and select publications

Breast Cancer | Tiffany A Traina, MD, FASCO Sep 29, 2023

Show notes

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 1: Biomarker-Based Decision-Making for Patients with Metastatic BRCA-Negative, Triple-Negative Breast Cancer (TNBC) — Tiffany A Traina, MD, FASCO

CME information and select publications

Breast Cancer | Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer Sep 29, 2023

Show notes

Featuring perspectives from Dr Hope S Rugo and Dr Tiffany Traina, including the following topics:

Introduction: "Isn't Oncology Depressing?" (0:00)
Checkpoint Inhibitors (13:37)
Antibody-Drug Conjugates (30:04)
HER2-Low Disease (54:25)
Other Agents Under Development (59:54)

CME information and select publications

Multiple Myeloma | Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma Sep 28, 2023

Show notes

Featuring an interview with Dr Paul G Richardson, including the following topics:

Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14)
Compassionate use of melflufen and belantamab mafodotin (12:08)
Current management strategies for newly diagnosed MM (16:30)
DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02)
Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected